Kyntra Bio (KYNB) Capital Expenditures (2014 - 2025)
Kyntra Bio (KYNB) posted Capital Expenditures of $9000.0 for Q3 2025, down 30.77% sequentially from $13000.0 in Q2 2025, and down 89.02% YoY from $82000.0 in Q3 2024.
Kyntra Bio (KYNB) Capital Expenditures (2014 - 2025) Analysis & Trends
Kyntra Bio has reported Capital Expenditures for 12 years, with the latest figure at $9000.0 in Q3 2025.
- Quarterly Capital Expenditures fell 89.02% year-over-year to $9000.0 in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $22000.0 (down 91.3% YoY) and the FY2025 annual result came in at $38000.0, down 85.71% from the prior year.
- Capital Expenditures slipped to $9000.0 in Q3 2025 per KYNB's latest filing, from $13000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $1.7 million in Q2 2021 and troughed at -$3.0 million in Q4 2022.
- A 5-year average of $316894.7 and a median of $518000.0 in 2021 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2021 and 2022: Capital Expenditures soared 275.89% in 2021, then tumbled 313.47% in 2022.
- Over 5 years, Capital Expenditures stood at $1.4 million in 2021, then tumbled by 313.47% to -$3.0 million in 2022, then grew by 27.35% to -$2.2 million in 2023, then surged by 106.51% to $141000.0 in 2024, then slumped by 93.62% to $9000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $9000.0, $13000.0, and $16000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 9,000.00 |
| Sep 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 13,000.00 |
| Jun 30, 2025 | 13,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Dec 31, 2024 | 141,000.00 |
| Dec 31, 2024 | 141,000.00 |
| Sep 30, 2024 | 82,000.00 |
| Sep 30, 2024 | 82,000.00 |
| Jun 30, 2024 | 14,000.00 |
| Jun 30, 2024 | 14,000.00 |
| Mar 31, 2024 | 29,000.00 |
| Mar 31, 2024 | 29,000.00 |
| Dec 31, 2023 | -2.17 Mn |
| Dec 31, 2023 | -2.17 Mn |
| Sep 30, 2023 | 684,000.00 |
| Sep 30, 2023 | 684,000.00 |
| Jun 30, 2023 | 993,000.00 |
| Jun 30, 2023 | 993,000.00 |